Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

Mulligan, G., Lichter, D. I., & Schu, M. (2014). Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood, 123(5), 632-639.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

"Show Me the Energy Costs"
Article

Effectiveness of interventions for the remediation of lead-contaminated soil to prevent or reduce lead exposure-A systematic review
Article

Variation in estimates of heat-related mortality reduction due to tree cover in US cities
Article

Promoting reproducibility and increased collaboration in electric sector capacity expansion models with community benchmarking and intercomparison efforts